#access
3 articles with this tag
HealthICIJ Investigation Links Keytruda Monopoly to Rising Health Costs
An ICIJ investigation of 37 countries reveals how Merck’s strategic business decisions for the cancer drug Keytruda drive up global public health costs.
HealthBiosimilar Stalemate: Why Lower Drug Costs Aren't Arriving
Unlocking the biosimilar puzzle: Discover why lower drug costs haven't materialized. Our analysis exposes the hidden forces stalling competition & impactin...
BusinessPayment Failures Signal Risk to Subscription Revenue
Uncover hidden risks in subscription revenue! Our analysis reveals why payment failures aren't just customer service—they signal a systemic vulnerability. ...